American Portfolios Advisors - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.

Quarter-by-quarter ownership
American Portfolios Advisors ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q3 2022$736
-15.8%
2300.0%0.00%
Q2 2022$874
-29.5%
2300.0%0.00%
Q1 2022$1,240
-80.9%
230
-52.1%
0.00%
Q4 2021$6,485
-24.8%
4800.0%0.00%
Q3 2021$8,621
+79.4%
480
+71.4%
0.00%
Q2 2021$4,805
-28.3%
280
-16.4%
0.00%
Q1 2021$6,700
+17.6%
3350.0%0.00%
Q4 2020$5,695
+2.5%
3350.0%0.00%
Q3 2020$5,558
-67.4%
335
-54.4%
0.00%
-100.0%
Q2 2020$17,023
+29.7%
7350.0%0.00%0.0%
Q1 2020$13,120
-17.3%
7350.0%0.00%0.0%
Q4 2019$15,865
+18.5%
7350.0%0.00%0.0%
Q3 2019$13,388
-29.7%
735
+37.4%
0.00%
-50.0%
Q2 2019$19,035
+18.0%
535
+11.5%
0.00%0.0%
Q1 2019$16,128
-6.5%
480
-8.6%
0.00%0.0%
Q4 2018$17,257
-46.1%
5250.0%0.00%
-50.0%
Q3 2018$32,004
+12.0%
525
-10.3%
0.00%0.0%
Q2 2018$28,5665850.00%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q1 2022
NameSharesValueWeighting ↓
Camber Capital Management LP 3,500,000$60,060,0002.02%
ACT CAPITAL MANAGEMENT, LLC 161,500$2,772,0001.42%
Rhenman & Partners Asset Management AB 950,000$16,302,0001.11%
MAVERICK CAPITAL LTD 5,761,073$98,860,0000.93%
Birchview Capital, LP 72,000$1,236,0000.74%
Bellevue Group AG 4,101,404$70,380,0000.69%
CM Management, LLC 50,000$858,0000.62%
Duquesne Family Office 1,000,000$17,160,0000.42%
OSTERWEIS CAPITAL MANAGEMENT INC 373,368$6,407,0000.33%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 67,000$1,149,0000.30%
View complete list of NEKTAR THERAPEUTICS shareholders